Efficacy and safety of bempedoic acid in patients with and without metabolic syndrome: Pooled analysis of data from four phase 3 clinical trials

Atherosclerosis. 2023 Aug:378:117182. doi: 10.1016/j.atherosclerosis.2023.06.973. Epub 2023 Jun 29.


Background and aims: Bempedoic acid significantly lowers low-density lipoprotein cholesterol (LDL-C) in patients with hypercholesterolemia but its effects in patients with metabolic syndrome (MetS) have not been well characterized. We sought to determine the efficacy and safety of bempedoic acid in patients with hypercholesterolemia by baseline MetS status.

Methods: This study used pooled data from four phase 3 studies. Using modified International Atherosclerosis Society guidelines, patients were grouped into two pools: those with and those without MetS. Patients with diabetes were excluded. Endpoints assessed change from baseline to week 12 in lipid and glycemic parameters and high-sensitivity C-reactive protein (hsCRP), and safety.

Results: The study included 936 patients with MetS (bempedoic acid, 648; placebo, 288) and 1573 without MetS (bempedoic acid, 1037; placebo, 536). Significant placebo-corrected reductions in LDL-C were observed with bempedoic acid (p < 0.0001), with a slightly larger decrease in patients with vs. without MetS (-22.3% vs. -18.4%; interaction p = 0.0472). Compared with placebo, bempedoic acid significantly (p < 0.0001) lowered total cholesterol, non-high-density lipoprotein cholesterol, apolipoprotein B, and hsCRP, with a similar magnitude of benefit observed between MetS categories. Triglycerides increased with bempedoic acid but only to a lesser extent than with placebo in patients without MetS (placebo-corrected difference, -4.4%; p = 0.02). Only patients with MetS experienced decreases in glycated hemoglobin (-0.07%; p < 0.0001) and fasting plasma glucose (-2.4 mg/dL; p = 0.002). Safety was comparable between MetS categories and treatment groups.

Conclusions: These data suggest that bempedoic acid is a suitable therapy for patients with and without MetS who require additional lipid lowering.

Keywords: Bempedoic acid; Fasting plasma glucose; HbA1c; Hypercholesterolemia; LDL-C; Metabolic syndrome; hsCRP.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Anticholesteremic Agents* / therapeutic use
  • C-Reactive Protein
  • Cholesterol
  • Cholesterol, LDL
  • Dicarboxylic Acids / adverse effects
  • Fatty Acids / adverse effects
  • Humans
  • Hydroxymethylglutaryl-CoA Reductase Inhibitors* / therapeutic use
  • Hypercholesterolemia* / diagnosis
  • Hypercholesterolemia* / drug therapy
  • Metabolic Syndrome* / diagnosis
  • Metabolic Syndrome* / drug therapy
  • Treatment Outcome


  • 8-hydroxy-2,2,14,14-tetramethylpentadecanedioic acid
  • Cholesterol, LDL
  • Hydroxymethylglutaryl-CoA Reductase Inhibitors
  • C-Reactive Protein
  • Fatty Acids
  • Dicarboxylic Acids
  • Cholesterol
  • Anticholesteremic Agents